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ABSTRACT
Analysis by gas chromatography-mass spectrometry and high performance liquid chromatography has
revealed organic residues in "mTc-pertechnetate obtained from "Mo-molybdate by extraction, using the
organic solvent methylethylketone (MEK). The organic residues have been identified as either
(i) low molecular weight carbonyl compounds such as formaldehyde, acetaldehyde and acetone,
presumably caused by the effects of y-radiation on MEK, or
(ii) condensation products resulting from the action of strong alkali on MEK during the extraction
process.
The quantities of organic residues varied from batch to batch of extracted pertechnetate; up to 40 ju.g
mL~' was found. When these compounds were tested, in rats, by addition to a pyrophosphate bone-
seeking radiopharmaceutical. the tissue distribution was not significantly different from that in the control,
which contained no added compound.
Assay for "Tc in MEK-derived pertechnetate indicated up to 10 /u.g mL~' of "Tc carrier. An assess-
ment of the biological effect of "Tc carrier was obtained by (i) red blood cell labelling, where 6 ng mL~' of
"Tc was sufficient to reduce labelling efficiency; and (ii) pyrophosphate tissue distribution, where a signifi-
cant effect was obtained in the presence of 10 jug mL~' of "Tc carrier.
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1. INTRODUCTION
Solvent extraction generators offer many advantages for the efficient production of "Tc. an isotope
used for a wide range of radiopharmaceutical applications [Boyd 1982]. These include low cost per unit
activity and the ability to use low specific activity "Mo, yielding a high radioactive concentration of "mTc
in the extract Of major concern, however, is a number of reports that 99mTc extracted with
methylethylketone ^MEK) has produced poor imaging quality in various 99mTc labelled
radiopharmaceuticals compared with those obtained with 99Tc extracted by adsorption chromatography
with alumina. For example, Wielaud et al. [1974] and Yeates et al. [1974] claimed poor labelling efficiency
of albumin microspheres with 99mTc obtained from an MEK extraction generator.
Two reasons have been suggested as the cause of poor labelling characteristics:
(a) the presence of organic residues in the MEK derived 99mTcO4~ [Boyd 1982]: and/or
(b) the presence of excessive quantities of 99Tc carrier [Richards 1975).
An investigation has been made of these possibilities.
2. EXPERIMENTAL
2.1 Materials
The following materials were supplied by the AAEC's Radioactive Products Research Section:
(i) Pertechnetate-M. Samples of MEK-extracted sodium pertechnetate (which conforms with BP
specifications) in isotonic saline solution were allowed to decay until the total activity was less
than 2 MBq.
(ii) Pertechnetate-Q- Samples of pertechnetate from the alumina chromatographic generator
(which conforms to BP specifications) with an average activity of 1 GBq.
(iii) MEK-generator washing. Samples of MEK flushed through the solvent generator.
Carrier Tc was obtained from Amersham International Ltd as "Tc-ammonium pertechnetate in 0.1 M
NH4OH.
Methylethylketone (MEK - Ajax Chemical Co, LR grade) was redistilled before use, after drying with
anhydrous potassium carbonate, and collecting the fraction boiling in the range 79 to 81°C at atmospheric
pressure.
Alkali-treated MEK was prepared by thoroughly mixing equal volumes of distilled MEK and 5 M
KOH for one hour. The two phases were separated and the MEK layer was evaporated to dryness under
N2. One hundred microlitres of redistilled MEK were added to redissolve the residue for further analysis.
Samples were irradiated in the AAEC's gamma irradiation pond.
Phenylhydrazine and 2,4-dinitrophenylhydrazine (BDH Chemicals) were used as derivatising agents
according to the method of Vogel [1979]. All other chemicals and solvents were AR grade (Ajax Chemical
Co).
2.2 Instrumentation
A Hewlett Packard model 5720A gas chromatograph (GC), equipped with a hydrogen flame ionisation
detector, was used with a 5 mm X 1 m glass column packed with 3 per cent OV-17 on Gas-Chrom Q
(Applied Science Lab.) and nitrogen as carrier gas (60 mL min""1).
An Altex model 330 isocratic high performance liquid chromatograph (HPLC), consisting of a model
110A pump and fixed wavelength (254 nm) u.v. detector, was used with a reverse phase RP-8, 10 jim
column (Brownlee Laboratories) and methanol-water (70:30) as the mobile phase.
Gas chromatography-mass spectrometry (GC-MS) was performed on a Finnigan 6110-9500 system, with
a 1 m column of 3 per cent OV-17 on Gas-Chrom Q using methane as carrier gas or, alternatively, on a 50
m capillary column coated with SE-30.
Chemical ionisation mass spectra of freeze-dried fractions from HPLC were obtained using the solid
probe inlet of the Finnigan system.
Polarograms were obtained using a Princeton Applied Research Corporation model 364 polarographic
analyser in the differential pulse mode. A three-electrode system, consisting of a dropping mercury
electrode with a controlled drop time of 1 s, a platinum counter electrode and a reference saturated calomel
electrode (SCE). was used. The polarographic scan was made from -0.2 V to -0.7 V (v. SCE) at a rate of 2
mV s ~ : and recorded on an Omnigrapiiic 2000 X-Y plotter.
Liquid scintillation counting was performed with a Packard Tri-Carb model 3255 liquid scintillation
spectrometer using Instagel (Packard) as the scintillation cocktail. Gamma-counting was carried out on
either a Nuclear Chicago gamma-scintillation counter or a Centronic ionisation chamber type 1G12-A20.
2.3 Biological Studies
2.3.1 Red blood cell labelling
The labelling method is a modification of one developed at Brookhaven National Laboratory [Smith
and Richards 1975]. About 6 mL of whole blood was collected from male Australian Albino Wistar
(AAW) rats in a 10 mL syringe containing 0.05 mL of 250 IU heparin (Commonwealth Serum Laboratory.
Melbourne) as an anti-coagulant Two millilitres of isotonic saline were added to freeze-dried renal
imaging agent (AAEC) which had been allowed to warm to room temperature. After five minutes of
incubation at room temperature, 0.2 mL of the solution was added to the blood sample contained in the
evacuated tube. This was again incubated at room temperature for five minutes, with intermittent gentle
mixing. The tube was centrifuged in the inverted position (so that the red blood cells settled on the
stopper and were readily removed by syringe) for five minutes at 1300 £.
Five millilitres of saline were added to the sample with shaking to dissolve all the residue. Of this
solution. 2 mL was taken into a separate tube, 300 mBq (0.05 mL) of pertechnetate-Q was added and the
solution thoroughly mixed
The tube was removed, in the inverted position, from the centrifuge and a 5 mL syringe (with all air
expelled) was inserted into the tube, keeping the needle point below the packed red blood cells. Two
millilitres of the red blood cells were gently drawn into the syringe and added to the tube containing the
pertechnetate/sample mixture. The solution was mixed and incubated at room temperature for another
five minutes with occasional stirring. After incubation, the tube was again centrifuged at 1500# for five
minutes. The supernatant was then carefully withdrawn into a separate tube. The activity was measured
in an ion chamber by first measuring the total activity and then the individual activity of the red blood
cells and the supernatant. The percentage of labelled red blood cells was calculated. The control
determination used 2 mL of saline instead of the sample solution. Each determination was performed in
duplicate.
2.3.2 Tissue distribution studies
A bone-seeking radiopharmaceutical, Technescan PYP, containing 12.0 mg of sodium pyrophosphate
and 3.4 mg of anhydrous stannous chloride, was obtained from Mallinckrodt as a freeze-dried preparation.
One millilitre of pertechnetate-Q (approximate activity 100 MBq mL~') was added to either
(i) 1 mL of isotonic saline containing the test compounds at appropriate concentrations; or
(ii) 2 mL of saline solution containing wTc carrier at the required concentration. This solution was
added to the PYP reagent, shaken and allowed to equilibrate for 10 min. A control was
prepared with no added test compound. A standard was made by diluting 90 juL of the solution
to 10 mL with water; two 1 mL samples of the diluted solution were then counted.
The radiochemical purity of the radiopharmaceutical was checked by thin-layer chromatography (TLC)
using Gelman ITLC strips developed in butanol-ethanol (1:1) mixture [Farrington 1983]. Less than 5 per
cent free pertechnetate was found in all samples.
Five female AAW rats were used for each set of samples. The rats were anaesthetised by placing them
in an ether box. Each rat was held in a rat restrainer and 90 juL of the test solution injected into the tail
vein. The treated rats were then placed in the metabolic cage. After 90 minutes, the rats were sacrificed,
ensuring that they had urinated fully before removal from the metabolic cage. The body weight of each
animal was recorded to 0.1 g. The rat was dissected and tissue samples of approximately 1 to 2 g were
collected. The following tissues were sampled:
Blood (approximately 1 mL) One kidney
Whole gut including caecum and rectum Skin (~ 10 cm2)
(subsampled later)
Bladder Muscle from hind leg
Whole liver (subsnmpled later) Both femurs (scraping off all clinging muscle)
Lungs Tail (about two thirds, including the site of
injection)
Spleen Urine
Heart
The weight of the whole liver was recorded and about 1 to 2 g sampled for counting. The sides of the
metabolic cage were washed with water and the washings collected together with the urine. These were
then weighed and a 1 mL aliquot put into the sample tube. The weights of all samples were recorded, and
the sample tubes and standards counted in the scintillation counter. Activities were corrected to the initial
counting time of the standard.
The final results were calculated, using the TISCON program [Maddalena 1983], both as a percentage
of the initial dose and as a percentage injected dose (% ID) per gram of tissue, where:
%ID = Total °rsan counts x m
Standard counts
o/ i-r, f • %ID% ID per gram of tissue = Total organ weight
For muscle, skin and blood the following factors were used to estimate the total organ weights [Maddalena
1983):
Muscle = 0.45 X body weight
Skin = 0.20 X body weight
Blood = 0.065 X body weight
Statistical analysis of the tissue distribution studies was performed using the Statistical Package for the
Social Sciences (SPSS version 8.0) on the University of Sydney's Cyber 70 computer. The tests included (i)
one-way analysis of variance (F-ratio), and (ii) the unpaired two-tailed t-test of significance [Nie et al
1975).
3. RESULTS AND DISCUSSION
3.1 Identification and Quantification of Organic Residues from MEK
3.1.1 Pertechnetate samples
Pertechnetate-M samples in which the 99Tc had decayed to a total activity of less than 2 MBq were
analysed. Several approaches were tried.
Direct GC-MS analysis was performed, after concentrating any organic residues, on extracts obtained
by passing 10 mL of pertechnetate-M through a Sep-pak cartridge (filled with ODS HPLC stationary
phase packing) then washing through with methanol. The methanol extract was reduced to ~ 25 juL; 1 juL
was then injected into the GC. Small amounts of seven components were detected, five of which had a
molecular ion with an m/e value of 142, corresponding to a molecular formula of C8H14O2, which could be
a dimer of MEK (mass 72) with the loss of two protons. The other components had m/e values of 114 and
140. The quantities detected were extremely small and varied from sample to sample.
On the basis of this evidence, it is likely that the residues contained at least one carbonyl function. If
this were the case, carbonyl derivatisation would improve the sensitivity of detection to the nanogram level
{Fung and Grosjean 1981].
Phenylhydrazone derivatives were prepared and chromatographed on OV-17 (initial temperature 150°C
for 6 min, then programmed to 230°C at 8°C per min). Although several peaks were observed, together
with batch-to-batch variation, GC-MS analysis indicated that some thermal decomposition had occurred
and that the mass spectra were difficult to interpret
Derivatisation with 2,4-dinitrophenylhydrazone (DNPH) yielded more stable compounds, but the
higher molecular weight led to long retention times at high operating temperatures (> 210°C) for
derivatives of kctoncs having molecular weights less than 100. Separation was therefore effected on reverse
phase HPLC; fractions which corresponded to peaks in the chromatogram were freeze-dried and analysed
by rnnss spectrometry.
By these means. pertechnetate-M samples were found to contain low molecular weight carbonyl
compounds (formaldehyde, acetaldehyde, acetone and MEK) following derivatisation by DNPH and
HPLC analysis. Batch-to-batch variation of the amounts of these carbonyls in pertechnetate-M samples
was of an order of magnitude, as shown in Table 1. Significant quantities of other carbonyl-DNPH
derivatives were not detected. These low molecular weight carbonyl compounds are present as
contaminants in the solvents used but at levels an order of magnitude less than the average found in
pertechnetate-M.
Akhtar et al. [1975] reported the presence of acetaldehyde and acetone among the y-radiolysis products
of MEK. which also included H2. CO, and CH4. They attributed the formation of acetaldehyde and
ethylene to an intramolecular rearrangement involving the transfer of a /J-hydrogen from an excited MEK
molecule. Ausloos and Paulson [1953] also found acetaldehyde and ethylene in the vapour and liquid
phase radiolysis of MEK. It is conceivable that some of the low molecular weight carbonyl compounds
are due to the effect of "Mo or"Tc y-radiation on the solvent MEK during the extraction process.
3.1.2 Alkali-treated MEK
In the production of 99Tc by the solvent generator method, the MEK must come into contact with
concentrated alkali to allow the formation of condensation products from the MEK. Narasimhan and
Mani [1975] studied the reaction and found traces of condensation products in the extract; however, these
were neither identified nor quantified.
The processes taking place in the solvent extraction generator were simulated by reacting alkali with
MEK at room temperature. The object of this simulation was to prepare larger quantities of all possible
contaminants of pertechnetate-M to enable identification of the minute amounts actually detected. The
conditions of simulation were varied, with KOH concentrations of 1 to 10 M and equilibrium times of one
hour to seven days. Longer equilibration time and stronger KOH solution led to altered product
distribution. „. ,, .,Dimethylhexenone
I
0
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Analysis of the resulting MEK by GC-MS revealed that the major product had an m/e of 144,
suggesting keto-alcohol, the condensation product of MEK. Four other products were formed in increasing
quantities as the KOH concentration, temperature and equilibration time increased. Two had molecular
weights of 126, and others had molecular weights of 140 and 180. The 126 products correspond to a
molecular formula of C8Hi4O and can be derived from the intermolecular condensation of MEK followed
by dehydration to the various structural isomers of I [Franke and Kohler 1923; Abbott et al. 1928]. The
180 compound (Ci2H2oO) is attributed to isophorone II, homoisophorone III or their structural isomers
[Ekeley and Howe 1923]. It is not understood how a compound with a molecular weight of 140 (C8H12O2)
could be formed from the condensation of MEK.
High performance liquid chromatography of alkali-treated MEK reacted with DNPH confirmed the
existence of molecules containing one carbonyl function each and having molecular weights of 144 and
140. However, derivatives corresponding to carbonyls of molecular weight 126 or 180 were not detected.
3.1.3 Generator washings
During the production of "TcO4"~ by the solvent extraction process, the MEK containing the extracted
pertechnetate is evaporated to dryness, before dissolution of the residue in saline. The apparatus is washed
at regular intervals to avoid the accumulation of contaminants in the system. Potentially, the generator
washings provide a good source for investigating the presence of organic residues. The washings contain
significant amounts of phthalate plasticisers, apparently as a result of minimal contact with plastic tubing
during washing.
The washings were concentrated 100-fold and analysed by conventional (OV-17) and capillary (SE-30)
column GC-MS. Apart from traces of common laboratory solvents, the principal species detected had
molecular ions of 126, 128 and 72 (the last indicating a breakdown in the GC-MS) and very small amounts
of 124, 140 and 142. The origin of the 128 peak is not clearly understood, but the molecular formulae
CyHiiOi (diketone) or C8H16O (monoketone) are possible candidates. The other compounds were
encountered in samples of alkali-treated MEK
3.1.4 Irradiated MEK samples
Studies were made of the effect of external y-irradiation on MEK, MEK-H2O (1:1) and MEK-5 M KOH
(1:1). Each sample received a dose of 0.5 or 1 x 104 Gy at the y-irradiation pond and was then treated in
the same manner as the alkali-MEK samples (see Section 3.1.2). Chromatograms of the irradiated MEK
and MEK-H2O samples showed only the solvent (MEK) peak. The irradiated MEK-KOH sample gave a
number of peaks which corresponded to those obtained from the unirradiated MEK-KOH, together with
small amounts of a substance with molecular ions of 124 (CgH|2O) and 138 (CsH|0O2). It appears that the
effect of y-irradiation on MEK is less significant than the effect of alkali.
3.2 Effect of MEK Residues on Sn(II)
The effect of residues from MEK and alkali-treated MEK on Sn(II) ions was analysed by polarography
to determine whether oxidation of Sn(II) or complexation of Sn(II) were possible mechanisms for the
production of contaminating organic residues. The half-wave potentials for Sn(II) and Sn(IV) are -0.40 V
and. -0.47 V (v. SCE) respectively. To obtain the Sn(II) wave, a supporting electrolyte of 1 M perchloric
acid was required. If chloride ion (CF) is added, a proportion of the Sn(II) is oxidised to Sn(IV). Total
tin content can be obtained (as Sn(IV)) using a supporting electrolyte containing 1 M HC1 and 3 M NaCl.
Methylethylketone has an influence on the polarographic behaviour of Sn(II); the peak current is
reduced but the half-wave potential remains the same. The reason for this effect is not understood, but it
may be due to adsorption phenomena at the mercury drop surface [Heyrovsky and Kuta 1966] and not to
a chemical reaction of the MEK
Because of these potential interferences from MEK and the saline in which the pertechnetate was
supplied, the standard addition technique was used. Two series of solutions were prepared: (a) 1 mL of
pertechnetate-M was added to 25 mL of 1 M perchloric acid followed by from 6 to 36 ju.g L~' of Sn(II); and
(b) 2 mL of pertechnetate-M was added to 25 mL 1 M perchloric acid followed by a lower range of Sn(II)
concentration (4 to 12 jag mL~').
The peak current versus added Sn(II) concentration for the two assays is plotted in Figure 1. The
intercept on the Sn(ll) axis indicates the extent of the reaction of TcO4~ with Sn(II). The Sn(II) equivalents
per millilitre of added TcO4~ were 1.0 ± 0.3 jug mL~' for (a) and 1.3 ± 0.3 /xg mL"1 for (b), and agree
within experimental error. When the dilution (25-fold) and the stoichiometric equivalence (2 moles TcO4~
to 3 moles Sn(II) is taken into account, this corresponds to 14 ± 5 jug "Tc per millilitre of pertechnetate-M
sample, which is the upper limit of "Tc found in the pertechnetate-M sample by liquid scintillation
counting (Section 3.3). Because of the dilution, this determination was much less accurate than required
for the identification of an effect which might be related to organic impurities. Consequently, it was
necessary n use the simulated alkali-treated MEK samples.
Methylethylketone was equilibrated with 5 M KOH for 1 hour in sufficient quantities to ensure at least
five 10 mL samples when the MEK layer was separated. Each of the 10 mL MEK layers was evaporated
under nitrogen and 25 mL of 1 M perchloric acid was added to the residue. Amounts of Sn(II) in the
range 6 to 36 ^ig mL~' were added and the peak current was plotted versus Sn(II) concentration (Figure 2).
It can be seen that a straight line passes though the origin.
In a second series, the MEK was equilibrated overnight (18 hours) with 5 M KOH with a lower Sn(II)
concentration range of 4 to 12 JMS. mL~'. Again, the line passes through the origin (Figure 2). From both
series of experiments, it is concluded that the organic residue from alkali-treated MEK has no detectable
effect on Sn(II).
In a third series, the equilibration was carried out in the presence of molybdate (300 mg per mL of
MEK). After equilibration for one hour, the MEK layer was treated as described above. The presence of
molybdate affected the shape and height of the Sn(II) peak. However, when the peak current at -0.4 V (v.
SCE) was plotted against Sn(II) concentration (Figure 2), a straight line was obtained with an intercept on
the [Sn(II)] axis at 1 jug mL"1. This value is presumed to be the Sn(II) equivalent of molybdate dissolved
in MEK.
3.3 Assay of Carrier "Tc in Pertechnetate-M
The /^-emitting "Tc in pertechnetate-M samples was determined by liquid scintillation counting. The
counting system was calibrated with known amounts of standard "Tc ammonium pertechnetate solution.
The theoretical count rate calculated from the concentration and decay constant of "Tc was correlated to
the measured count rate. Over the range 5 to 12000 ng mL~', the agreement averaged 98 + 4 per cent
Table 2 shows the amounts of "Tc measured in different batches of pertechnetate-M; the overall range
was 0.5 to 10 ju.g mL~'.
3.4 Biological Studies
3.4.1 Red blood cell (rbc) labelling studies
The site and mechanism of "Tc binding to rbc components have been reported by Dewanje [1974]
and Rehani and Sharma [1980]. Apparently, the process of pertechnetate binding to the rbc involves
passive diffusion of pertechnetate into the cell. There appears to be no mechanism inside the cell to
reduce pertechnetate since, in the absence of a reducing agent intracellular 99mTcO4~~ ion readily diffuses
when the rbc is suspended in normal saline. Stannous ion (Sn(II)) then reduces "TcO4~ ion to a lower
valence state, probably Tc(V). and is then believed to bind to the beta chain of the globin.
Since the binding of "Tc depends on the ability of the 9l)TcO4~~ ion to be reduced by Sn(II) ions, any
interference with this process will manifest itself by a lowering in labelling efficiency. Consequently, the
rbc labelling method was used to investigate the effects of organic residues, molybdate, perrhenate and
"Tc carrier.
Alkali-treated MEK was used to determine the effect of organic residues on rbc labelling.
Methylethylketone which had been equilibrated with 5 M KOH for one hour was divided into 5 and 40
mL portions. These were then evaporated under nitrogen and used for the labelling experiment The rbc
labelling efficiencies, expressed as percentages, are given in Table 3.
The rbc labelling efficiency for the 40 mL sample was lower than those obtained for the 5 mL sample
and the control. However, using the t-test, there is no significant difference between the two sets of results
and the control. This means that the organic residue from 40 mL of alkali-treated MEK has no significant
effect on the rbc labelling efficiency.
The effect of molybdate was tested because of the possibility of molybdate contamination due to a
slight variation in the extraction process. The amount of molybdate, measured by detecting 740 keV
photons of "Mo in a dose calibrator or in an Nal (Tl) detector coupled to a pulse height analyser [USP
1975], was usually less than 5 ppm. As can be observed in Table 3, the percentage rbc labelled in the
presence of 10 ppm molybdate was very high (99.4%), indicating that at this level molybdate does not affect
the efficiency.
The presence of perrhenate in pertechnetate samples is due to trace impurities of rhenium and tungsten
in the molybdenum trioxide target material [Boyd 1982]. Rhenium impurities undergo neutron activation
as follows:
185Re (n,y) 186Re ; t« = 90.6 h
187Re(n,y) 188Re ; t,5 = 17.0 h
When neutron-activated, tungsten undergoes the following reaction:
(n, y) ™W (n, y)
The amount of rhenium in the final pertechnetate solution depends on the initial amounts of rhenium and
tungsten impurities in the target material.
When 100 ppm of perrhenate was used in the rbc labelling study the labelling efficiency was high
(99%). The result indicates that at this level perrhenate does not affect the rbc labelling efficiency.
The "Tc carrier effect on the rbc labelling efficiency was investigated by diluting the 99Tc serially and
spiking it with freshly eluted "mTc pertechnetate-Q. From Table 4 it can be seen that the percentage of rbc
labelled decreases with increasing concentration of "Tc carrier. There is a relatively sharp drop in the
percentage of rbc labelled for "Tc concentrations in the range 5.6 - 56 ng mLT1, resulting in about 70 per
cent labelling efficiency. A further increase in the amount of "Tc did not produce a corresponding
reduction in the percentage rbc labelled.
3.4.2 Effect of carbonyl compounds on tissue distribution
Chemical analysis of pertechnetate-M revealed the presence of several low molecular weight carbonyl
compounds, including formaldehyde, acetaldehyde, acetone and MEK. These carbonyl compounds were
studied to determine whether they have an effect on the tissue distribution of radiopharmaceuticals.
A bone-seeking radiopharmaceutical containing pyrophosphate was used since most of the poor quality
scans reported were associated with the pertechnetate-M when used in bone studies. Throughout the
experiment, the same batch of lyophilised pyrophosphate sample was used to avoid batch variation which
might occur in the manufacture of the radiopharmaceutical kit Other controlled parameters were the age
and sex of the animals, both of which affect the uptake and tissue distribution of bone agent [Thrall et al.
1974; Wilson 1981]. Thus only female rats between the ages of 7 and 8 weeks were used.
The quantity of test compound added to the radiopharmaceutical was approximately ten times the
average value found in the assayed pertechnetate-M samples (except for MEK, which was used at twice the
average amount). With this elevated value, any change that might occur in the tissue distribution would be
enhanced and thus more readily detected. Subsequent experiments at lower concentrations would then be
used to ascertain the minimum detectable level of the effect
Acetonylacetone was used as a representative of a dicarbonyl compound to determine if such a
structural group affects the distribution of the bone-seeking agent Table 5 shows the tissue distribution
(presented as %ID) of 99mTc-pyrophosphate in the absence and presence of formaldehyde, MEK,
acetaldehyde and acetonylacetone. Table 6 shows the same results as %ID per gram of tissue. The latter
representation enables a more accurate comparison of uptake by different tissues since the results are
compared for the same amount of each tissue. Also included in the latter are the ratios of femur to blood
and femur to muscle (calculated for individual animals and then averaged). This value indicates the
contrast between the activity in the bone and surrounding tissues.
Table 7 shows a statistical analysis of the results. There were significant differences for kidney, skin,
lung, stomach and femur tissues at P = 0.05. A t-test was then performed comparing the carbonyl
compounds to the control. Significant differences were observed for acetonylacetone in liver, skin and
femur tissues and in the femur-to-blood ratio; for acetaldehyde, significant differences were found for
kidney, skin and lung tissues. In the case of MEK, skin and blood were significantly different and for
formaldehyde only the skin showed any significant difference.
Since the radiopharmaceutical was a bone-seeking agent, of most interest is the difference that affects
distribution in the bone. A change in bone distribution was observed only in the presence of
acetonylacetone, Le. a dicarbonyl compound.
3.4.3 Effect of 99Tc carrier on tissue distribution
The assay of "Tc carrier in pertechnetate-M samples showed the presence of 9*Tc in the range 0.5 to 9.9
Mg niL"1. Red blood cell labelling studies showed that even at nanogram quantities the presence of "Tc
affects the labelling efficiency. At microgram levels, the rbc labelling efficiency is only about 60 to 70 per
cent Because the amounts of "Tc in the pertechnetate-M samples are in the microgram range, tissue
distribution studies were carried out to investigate the effect of 00To at that level.
After the addition of "Tc. the quality of the radiopharmaceutical was monitored by ITLC. which
showed that it had insufficient free pertechnetate to interfere with the distribution of "Tc-pyrophosphate.
The tissue distribution studies were performed at three different "Tc concentrations corresponding to
two. three and five times the maximum amount of "Tc found in 20 batches of pertechnetate-M sample.
The results are presented in Tables 8 and 9 as %ID and %ID per gram of tissue respectively.
An increase in liver uptake and a reduction in femur uptake is to be expected if "Tc carrier affects
tissue distribution. This can be observed by comparing the values of tissue uptake for different "Tc
concentrations to that of the control. There is a considerable increase in liver uptake at 56 /ig mL~' of
"Tc and a subsequent decrease in the femur uptake. The same trend was observed at the other wTc
concentrations although they were not so pronounced. The femur-to-blood ratio decreased as the "Tc
concentration increased; this indicated a larger blood uptake causing background activity to be high, thus
resulting in poor bone imaging. This trend was also observed for femur-to-muscle ratio, although in this
case there were large variations in the values within a group owing to variations in muscle sampling.
A statistical evaluation of the results is given in Table 10. There are significant differences for liver,
spleen, lungs, blood, urine, bladder and femur tissues and for femur-to-blood ratio. The t-test indicates
highly significant differences for liver, blood, and femur tissues and for femur-to-hlood ratio at 56 jug mL~'
of "Tc; at 33.6 jug mL~', the differences for femur tissue and femur-to-blood ratio are also highly
significant. Significant differences are observed at P = 0.05 for liver, spleen and lung tissue and for blood
This study indicates that pyrophosphate distribution is affected by the amount of "Tc in the
radiopharmaceutical.
The radiopharmaceutical systems used in these biological studies were chosen because of adverse
reports about MEK-derived pertechnetate. This has not been the case for other bone-seeking agents such
as methylene disphosphonate (MDP) or pertechnetate from a chromatographic generator. In the case of
MDP, it is possible that the equilibrium constant for the formation of the Tc-MDP complex is larger than
that for pyrophosphate. so all "Tc and "Tc is complexed, and good bone imaging results. Of equal
importance is the fact that most contemporary MDP formulations consist of a large excess of free ligand,
whereas the brand of pyrophosphate used in this study (Mallinckrodt Technescan PYP) is formulated to
contain equivalent amounts of pyrophosphate and tin. and hence could provide only a low concentration
of free pyrophosphate ligand. Consequently, the effect of Tc carrier might be more significant in
Mallinckrodt pyrophosphate than in most MDP formulations containing large excesses of free ligand.
Usually, chromatographic generators are first eluted four days alter loading, by which time "Tc levels
have risen to about 50 per cent of the loaded "Mo. For example, a typical generator loaded with 2 Ci (74
GBq) of "Mo and first eluted 67 hours later will yield about 2 jug of "Tc in 5 mL of eluant At this
concentration (0.4 jug mL~'). the "Tc carrier is expected to interfere with rbc labelling only. (The
instructions accompanying chromatographic generators carry such a warning.)
The presence of non-uniform amounts of "Tc in pertechnetate-M samples can be attributed to two
variations in the extraction and dispensing procedures:
(i) The time between successive extractions of the "Mo-"mTc mixture with MEK varies. When a
generator is loaded, there is 2 /ig of "Mo (calculated as Mo atoms) per curie (37 GBq) of "Mo
activity. The amount of technetium (as "Tc and "mTc) at the time of extraction is governed by
the half-life of "Mo (67 h) and the time elapsed since the previous extraction. The amount of
"Tc extracted will usually be small (0.3 mg Ci~' at 24 h) unless the sample of "Mo is very old
(i.e. many half-lives since the previous extraction).
(ii) Freshly extracted "Tc decays with a much shorter half-life (t^ = 6 h) thereby accumulating
"Tc at a rate greater than that inside the generator. For example, if 15 mCi (~ 0.5 GBq) of
"Tc is required for injection and the time for dispensing the pertechnetate is 24 hours earlier.
240 mCi (~ 8 GBq) will be extracted. The technetium content of a freshly extracted 240 mCi
sample is about 45 ng. Thus the total technetium in the 15 mCi used 24 hours later will be 45
ng. On the basis of these results, if 15 mCi of pertechnetate was then used for rbc labelling
studies, it would reduce the labelling efficiency significantly, but would not affect the tissue
distribution of Tc-pyrophosphate complex.
When a sample of "Mo-"mTc of particularly high activity is extracted with MEK, then taken up in a
fixed volume of saline, the "mTc activity could be greater than desired for dispensing. If the sample is
allowed to decay to the desired level of activity, the accumulation of "Tc per Ci of activity will increase by
a factor of 16 for every 24 hours of decay. This is the only means by which "Tc levels in pertechnetate
could rise high enough to interfere with the pyrophosphate bone imaging.
4. CONCLUSIONS
Analysis by HPLC and GC-MS of sodium pertechnetate derived by extraction of alkaline
pertechnetate-molybdate mixtures has revealed the presence of organic residues in quantities which vary
widely from batch to batch. The principal components were identified as the low molecular weight
carbonyl compounds formaldehyde (up to 3.2 jug mL~'), acetaldehyde (up to 34.2 jug mL~'), acetone (up to
6.1 /xg mL~') and MEK (up to 3.7 mg mL~').
When these compounds were tested by addition to a pyrophosphate bone-seeking radiopharmaceutical
and injection into rats, the tissue distribution was not significantly different from that in the control, even
when the added amounts were up to ten times the maximum levels specified above. These low molecular
weight carbonyl compounds seem to result from the radiation-induced decomposition of MEK.
In addition, compounds were detected at very low levels (< 1 jug mL~') and suspected of being derived
from alkaline condensation reactions of MEK followed by dehydration. Sample mixtures of such
compounds were prepared and tested with the sensitive rbc labelling technique. Again, with added
amounts of condensation products of the order of 1 mg mL~', there was no significant difference from the
control.
Other possible contaminants (molybdate and perrhenate) did not affect rbc labelling studies.
Polarographic studies of the effect of various organic contaminants on the radiopharmaceutical reducing
agent Sn(II) gave similar results. It is concluded that organic contaminants derived from MEK do not
affect the performance of radiopharmaceuticals.
However, "Tc carrier at nanogram levels produced a reduction in rbc labelling efficiency. This
reduction was observed at "Tc concentrations as low as 6 ng mL~', at which level the percentage rbc
labelled dropped to about 95 per cent compared to 99 per cent for the control. Further reduction was
observed at 1 1 ng mL~' (corresponding to about 84 per cent labelled). Subsequent increases in "Tc did
not produce corresponding reductions in labelling efficiency. Values of about 60 per cent were obtained
for microgram amounts of "Tc.
An assay of pertechnetate-M samples revealed microgram quantities of "Tc, Le, levels far in excess of
those needed to reduce the rbc labelling efficiency. Animal tissue distribution studies with two, three and
five times the maximum amount detected showed that tissue distribution of pyrophosphate is susceptible to
the amount of "Tc at these levels. This was observed as a highly significant reduction in bone uptake and
an equally significant increase in liver uptake. The effect apparently increases with an increase in added
"Tc. Thus, it would seem that "Tc affects the characteristics of pyrophosphate radiopharmaceuticals.
On the basis of these experiments, maximum levels of "Tc in "mTc can be defined for particular
applications. For example, in rbc labelling, 6 ng mLH of "Tc carrier appears to be sufficient to influence
the labelling, whereas a significant effect on pyrophosphate distribution in bone is found only above 10 jug
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TABLE 1
AMOUNTS OF CARBONYL COMPOUNDS FOUND IN PERTECHNETATE-M SAMPLES
AAEC
Code No.
33151-14
-15
-16
-17
-18
-19
-20
-22
-23
-24
-25
-26
-27
-28
-29
-30
-31
-33
Batch
No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Formaldehyde
0.45
1.50
1.20
1.16
2.67
1.66
2.10
1.08
2.16
2.14
2.82
1.82
3.03
2.61
3.19
1.53
3.18
2.14
Concentration
Acetaldehyde
16.72
4.05
2.19
19.39
4.75
3.38
5.91
5.80
26.86
34.15
3.36
2.32
11.30
11.80
14.96
0.69
14.09
0.00
(MS mL-')
Acetone
0.00
0.72
0.77
0.00
3.30
3.47
4.48
3.67
1.51
2.58
4.38
3.03
3.98
3.05
3.86
6.07
4.66
0.27
MEK (X 103)
1.380
0.001
0.001
1.270
0.010
0.006
0.034
0.061
3.670
2.060
0.013
0.005
0.060
0.179
0.057
0.007
0.242
0.020
TABLE 2
AMOUNT OF "Tc IN DIFFERENT BATCHES OF PERTECHNETATE-M SAMPLES
AAEC
Batch No.
33151-24
-43
-46
-49
-50
-51
-54
-55
-59
-56
Batch
No.
1
2
3
4
5
6
7
8
9
10
Amount of
"Tc
(HZ mlT1)
4.4
1.4
2.6
6.2
1.8
3.9
2.6
3.4
3.3
0.8
AAEC
Batch No.
33151-57
-58
-60
-61
-62
-64
-65
-66
-67
-69
Batch
No.
11
12
13
14
15
16
17
18
19
20
Amount of
"Tc
(UK mlT1)
2.0
0.5
9.9
5.3
8.3
5.0
2.8
7.5
1.4
8.2
12
TABLE 3A
THE EFFECT OF ORGANIC RESIDUES ON
RED BLOOD CELL LABELLING EFFICIENCY
rbc Labelling
Efficiency (%)
Control
5 mL sample
40 mL sample
99.0
99.1
96.7
97.9
95.5
95.0
Each value is an average of two
determinations. The two sets of
readings were obtained on separate
days.
TABLE 3B
THE EFFECT OF MOLYBDATE AND PERRHENATE ON THE
RED BLOOD CELL LABELLING EFFICIENCY
Cone. rbc Labelling
(/xg .a"1) Efficiency (%)
Control 98.8
Molybdatc 10 99.4
Pcrrhcnatc 100 99J_
Value is an average of two determinations.
TABLE 4
THE EFFECT OF "Tc CARRIER ON THE
RED BLOOD CELL LABELLING EFFICIENCY
Cone, of "Tc
(ns mlT1)
Control
5.6
11.2
56.0
112.0
8440.0
rbc Labelling
Efficiency (%)
98.9 ± 0.6
95.0 ± 1.0
83.0 ± 1.0
68.0 ± 0.7
65.6 ± 1.0
60.8 ± 3.0
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TABLE 5
TISSUE DISTRIBUTION OF 99mTc ACTIVITY IN RATS
FOR PYROPHOSPHATE WITH ADDED CARBONYL COMPOUNDS
% Iniected Dose (Average of 5 Rats)
Tissue
Liver
Spleen
Kidney
Muscle
Skin
Lungs
Heart
Blood
Urine and
Bladder
Stomach
Gut
Tail
Femur
Body
Weight (g)
Control
10.9 ± 2.8
0.2 ± 0.06
1.3 ± 0.2
2.7 ± 1.1
2.1 ± 0.4
0.09 ± 0.03
0.03 ± 0.01
1.12 ±0.14
33.3 ± 3.2
0.27 ± 0.24
2.6 ± 1.7
0.87 ± 0.43
1.27 ± 0.03
144.0 - 168.0
Formaldehyde
11.2± 1.7
0.27 ± 0.08
1.31 ±0.18
*2.31 ±0.49
2.92 ± 0.35
0.08 ± 0.00
0.02 ± 0.00
1.08 ± 0.08
33.7 ± 3.3
1.1 ± 1.1
3.3 ± 1.4
1.1 ±0.1
1.30 ±0.06
153.8 - 179.1
MEK
10.4 ± 3.1
0.24 ±0.10
1.13 ± 0.08
2.4 ± 1.0
3.00 ± 0.29
0.09 ± 0.02
0.03 ± 0.00
1.09±0.1C
31.6 ±5.1
0.34 ± 0.20
2.9 ± 1.1
1.6 ± 0.6
1.38 ± 0.08
150.7 - 202.3
Acetaldehyde
10.5 + 2.4
0.43 ±0.15
1.65 ± 0.12
2.17 ±0.15
3.06 ± 0.51
0.16 ± 0.05
0.03 ± 0.001
1.15 ±0.32
37.1 ± 1.5
0.14 ±0.07
2.6 ± 1.6
1.94 ± 0.33
1.35 ±0.25
144.9 - 180.3
Acetonylacetone
8.7 ± 1.6
0.28 ±0.16
1.32 ± 0.09
2.09 ± 0.23
3.31 ±0.19
0.10 ± 0.008
0.03 + 0.00
1.52 ± 0.14
31.7 ± 7.5
0.82 ±0.11
2.78 ± 0.93
1.54 + 0.52
1.27 ± 0.12
185.3 - 207.9
Results shown are the average ± standard deviation of
determinations on 5 rats except those indicated by * where
outlying values (>2 s.d.) have been eliminated.
TABLE 6
DATA OF TABLE 5 EXPRESSED AS % INJECTED DOSE PER GRAM OF TISSUE
% Injected Dose/g Tissue (Average of 5 Rats)
Tissue
Liver
Spleen
Kidney
Muscle
Skin
Lungs
Heart
Blood
Urine and
TD1 nr\A~~Bladder
Stomach
Gut
Tail
Femur
Ratio
Femur/
Blood
Femur/
Muscle
Control
1.44 + 0.44
0.41 ±0.11
0.95 ±0.18
0.049 ± 0.025
0.069 ±0.0 11
0.092 ±0.019
0.051 ± 0.008
0.1 12 ±0.011
1.21 ± 0.20
0.079 ± 0.063
0.20 ±0.1 3
0.45 ± 0.23
3.49 ± 0.30
3 1.3 ±4.3
86 ±36
*97 ± 29
Formaldehyde
1.47 ±0.21
0.44 ± 0.14
0.98 ±0.12
0.032 ± 0.006
0.088 ± 0.008
0.087 ± 0.006
0.044 ± 0.002
0.101 ± 0.008
1.12 ±0.17
0.47 ± 0.39
0.25 ± 0.10
0.58 ± 0.05
3.40 ± 0.25
33.7 ± 3.2
*114±26
MEK
1.26 ± 0.53
0.38 ±0.18
0.87 ± 0.16
0.031 ± 0.014
0.085 ±0.010
0.085 ±0.010
0.048 ± 0.010
0.095 ± 0.008
1.43 ± 0.36
0.135 ± 0.076
0.23 ±0.13
0.56 ±0.1 8
3.13 ± 0.46
32.9 ± 5.1
113 ±37
*127 ± 25
Acetaldehyde
1.07 ±0.31
0.67 ± 0.32
1.21 ±0.17
0.029 ± 0.004
0.092 ±0.018
0.148 ± 0.039
0.054 ±0.0 11
0.105 ± 0.025
1.43 ±0.32
0.047 ±0.031
0.17 ±0.11
0.69 ± 0.09
3.39 ± 0.26
35 ± 13
*28.8 ± 2.4
117 ±9
Acetonylacetone
0.94 ± 0.27
0.36 ± 0.17
0.86 ± 0.04
0.023 ± 0.002
0.085 ± 0.004
0.089 ± 0.007
0.043 ± 0.004
0.119 ±0.010
1.38 ±0.38
0.204 ± 0.058
0.171 ± 0.055
0.50 ±0.12
2.74 ± 0.32
23.0 ± 2.2
117 ± 10
Results shown are the average ± standard deviation of
determinations on 5 rats except those indicated by * where
outlying values (>2 s.d.) have been eliminated.
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TABLE 7
STATISTICAL EVALUATION OF DATA IN TABLE 6
Tissue
Liver
Spleen
Kidney
Muscle
Skin
Lung
Heart
Blood
Stomach
Tail
Femur
Ratio
Femur/Blood
S =
Analysis
F Ratio
1.845
1.871
4.699
2.019
3.117
8.438
1.735
2.205
4.234
1.744
4.215
2.213
significant
of Variance
Significance
NS
NS
S
NS
S
S
NS
NS
S
NS
S
NS
NS = not
t-test
Significance
Significant for acetonylacetone
NS
Significant for acetaldehyde
NS
All significant
Significant for acetaldehyde
NS
Significant for MEK
NS
NS
Significant for acetonylacetone
Significant for acetonylacetone
significant at P = 0.05
TABLE 8
DISTRIBUTION OF 99mTc PYP IN RATS
EFFECT OF ADDED "Tc
Tissue
% Injected Dose
Control 56 ju.g mL"
Liver
Spleen
Kidney
Muscle
Skin
Lungs
Heart
Blood
Urine and
Bladder
Stomach
GI Tract
Tail
Femur
Body Weight (g)
9.24 ± 0.93
0.30 + 0.06
1.25 ±0.26
1.92 ±0.28
2.29 ± 0.34
0.08 ± 0.02
0.02 ± 0.01
1.05 ±0.16
30.6 ± 4.0
0.34 ±0.19
2.9 ± 1.4
1.04 ±0.54
1.28 ±0.03
163.3 - 189.6
13.21 ± 1.7
0.66 ± 0.05
1.08 ± 0.10
2.5 ± 1.1
2.33 ± 0.25
0.10 ± 0.03
0.03 ± 0.01
1.30 ±0.21
3 1.4 ±3.0
0.53 ± 0.63
1.73 ±0.64
1.67 ± 0.26
1.18 ±0.06
137.1 - 172.6
13.0 ± 1.3
0.48 ±0.10
1.28 ±0.12
2.42 ± 0.52
2.70 ± 0.27
0.13 ± 0.05
0.04 ± 0.02
1.486 ± 0.034
28.7 ± 3.3
0.164 ±0.061
1.21 ± 0.21
1.63 ± 0.48
1.16 ± 0.06
162.7 - 187.5
22.0 ± 3.4
0.59 ±0.10
1.13 ±0.12
2.32 ± 0.47
3.26 ± 0.61
0.14 ±0.02
0.04 ± 0.08
1.81 ± 0.24
26.8 ± 4.4
0.214 ± 0.085
* 1.60 ±0.49
0.98 ±0.13
0.90 ± 0.05
182.8-213.1
Results shown are the average ± standard deviation of
determinations on 5 rats except those indicated by * where
outlying values (>2 s.d.) have been eliminated.
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TABLE 9
DATA OF TABLE 8 EXPRESSED AS % INJECTED DOSE PER GRAM OF TISSUE
Tissue Control
% Injected Dose/g Tissue
22.4 ULS mL~] 33.6 us mL"1 56 Mg niL
Liver
Spleen
Kidney
Muscle
Skin
Lungs
Heart
Blood
Urine and
Bladder
Stomach
GI Tract
Tail
Femur
1.16 ±0.11
0.41 ± 0.10
0.84 ± 0.20
0.027 ± 0.006
0.069 ± 0.009
0.076 ±0.015
0.044 ± 0.012
0.103 ± 0.020
1.20 ± 0.19
0.096 ± 0.053
0.21 ±0.11
0.38 ±0.16
3.19 + 0.23
1.95 ± 0.37
0.91 ± 0.17
0.843 ± 0.096
0.037 ± 0.018
0.076 ±0.010
0.111 ±0.026
0.054 ± 0.009
0.140 ± 0.021
1.36 + 0.12
0.23 ± 0.25
0.131 ±0.058
0.724 ± 0.074
3.48 ± 0.42
1.84 + 0.29
0.71 ±0.16
0.941 + 0.058
0.031 ± 0.008
0.078 ± 0.005
0.122 ± 0.002
0.066 ±0.0 17
0.143 + 0.009
0.86 ± 0.13
0.080 ± 0.036
0.086 ± 0.020
0.58 ±0.12
2.93 ± 0.23
2.71 ±0.48
0.80 ± 0.20
0.76 ±0.13
0.027 ± 0.005
0.084 ±0.017
0.140 ± 0.014
0.059 ± 0.006
0.155 ± 0.019
1.18 ±0.19
0.058 ± 0.028
*0.100 ±0.031
0.262 ± 0.027
1.992 + 0.078
Ratio
Femur/Blood
Femur/Muscle
3 1.9 ±5.1
*133 ± 19
25.6 ± 4.9
*124 + 32
20.50 ± 0.60
*107± 12
12.9 ± 1.1
*81.2 ± 5.8
Results shown are the average ± standard deviation of
determinations on 5 rats except those indicated by * where
outlying values (>2 s.d.) have been eliminated.
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TABLE 10
STATISTICAL EVALUATION OF DATA IN TABLE 9
Tissue
Liver
Analysis of Variance
F Ratio Significance
t-test
Significance
13.33 All significant Highly
signficant for (3)
Spleen
Kidney
Muscle
Skin
Lungs
Heart
Blood
Urine and
Bladder
Stomach
Gut
Tail
Femur
Ratio
Femur/Blood
6.94
1.06
0.87
1.15
7.29
2.62
6.26
6.31
2.31
1.50
1.30
23.59
19.89
S
NS
NS
NS
S
NS
S
S
NS
NS
NS
S
S
All significant
NS
NS
NS
All significant
NS
(1) and (3) highly significant
(2) significant at P = 0.05
Significant for (2)
NS
NS
NS
(1) significant at P = 0.05
(2) and (3) highly significant
(1) Not significant
(2) and (3) highly significant
S = significant NS = not significant
(1), (2) and (3) denotes the level of "Tc carrier correspond-
ing to 22.4, 33.6 and 56.0 jug mL~' respectively.
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FIGURE 1 Effect of pertechnetate on Sn(II) (a) 1 mL pertechnetate, and (b) 2 mL pertechnetate
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FIGURE 2 Effect of alkali treated MEK on Sn(II) (a) MEK equilibrated with KOH for 1 hour, (b) MEK
equilibrated with KOH overnight, and (c) MEK equilibrated with KOH and molybdate
